Evidence Summary
- Evidence Level
- Moderate
- Mechanism
- Enrollment: Actual, Sponsor Type: Other, Unknown / General
- Safety
- Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
- Dosing
- See linked studies/trials for reported doses and durations; typical protocols vary widely.
Leukotriene receptor antagonist used as add-on in MCAS and sometimes respiratory phenotypes in long COVID. 10mg daily. Supported by observational MCAS data and urticaria RCTs. Low risk; consider for MCAS-overlap with incomplete antihistamine response.
Clinical Trials
1 trial(s) registered
| NCT ID | Title | Phase | Status |
|---|---|---|---|
| NCT04695704 | Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19: | Phase 3 | Terminated |
Key Studies / References
- See linked studies